Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10953994 | 0.91 | HTT (0.61) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL431541 | 0.90 | HTT (0.72) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL10490892 | 0.89 | LMNA (0.57) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL13055383 | 0.89 | LMNA (0.80) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL6170645 | 0.89 | HTT (0.70) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL8197237 | 0.87 | LMNA (0.67) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL5240928 | 0.87 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL29270787 | 0.87 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL1419600 | 0.87 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL17641102 | 0.87 | HTT (0.68) | LMNASMN1; SMN2HTTTGM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731645-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | Carmot Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024264014-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | CARMOT THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | claimed |
| CN-115677551-A | Preparation process of 2-oxopyrrolidine-3-ethyl formate | 武汉市振邦生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731645-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS AND PRECURSORS THEREOF | Carmot Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4711355-A1 | CRYSTAL FORM OF LIPOPROTEIN COMPOUND AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-4512979-A | Dipeptides containing thialysine and related amino acids as antihypertensives | MERCK & CO., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4283434-A | FOR FOODS | NUTRASWEET COMPANY THE | 1981-08-11 | — | — | US | disclosed |
| US-4090027-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4077978-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-3996374-A | Isoindole derivatives as appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3992437-A | Polyhydrophenanthrene derivatives | STERLING DRUG INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3932482-A | CARDIOTONIC | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | LMNA 1803/4885SMN1; SMN2 4729/4885HTT 2283/4885 |
| US-20260116927-A1 | Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof | GLP1R, GIPR, GRPR | LMNA 4007/4885SMN1; SMN2 2208/4885HTT 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.